Metastatic Breast Cancer Treatment After Abemaciclib-Related Liver Injury — Case 5
This breast cancer diagnosis at a glance
- Stage at diagnosis
- Stage IV
- Sex
- female
- Treatment
- hormone therapy and targeted therapy
- Outcome
- Care Ongoing
Treatment course, step by step
- She started fulvestrant with abemaciclib.
- Abemaciclib was stopped after severe liver injury on day 58.
- After liver tests improved, she switched to palbociclib and had no recurrent liver dysfunction.
What happened, in summary
A 72-year-old woman with metastatic breast cancer was treated with fulvestrant and abemaciclib. On day 58, her ALT rose to 369 IU/L. Abemaciclib was discontinued, and the ALT level fell by about half over the next 2 months. The drug was not reintroduced. After her liver tests improved, she switched to palbociclib so that CDK4/6 inhibitor treatment could continue. Her ALT remained stable after the change, with no recurrence of the severe liver dysfunction described during abemaciclib therapy. The treatment change allowed CDK4/6 inhibitor therapy to continue without recurrent liver toxicity.
Where this story comes from
This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full
How we source and attribute stories Accuracy and limitations
Collections this story belongs to
- Stage 4 Breast Cancer 295 stories
- Abemaciclib for Breast Cancer 25 stories
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer